MelaFind Chosen as One of Top 10 Medical Innovations for 2013 by Cleveland Clinic

Criteria for Inclusion are Significant Clinical Impact, High Probability of Commercial Success, and Significant Human Interest

        Print
| Source: MELA Sciences, Inc.

NEW YORK, Nov. 5, 2012 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed MelaFind®, a breakthrough device intended to help dermatologists detect melanoma when it is still curable, announced today that it has been included in the Top 10 Medical Innovations for 2013 compiled by the Cleveland Clinic.

"To be selected for inclusion into this group is a great honor and testament to the clinical and commercial potential for MelaFind," said Joseph V. Gulfo, MD, President & CEO of MELA Sciences. "Now in the second half of our commercial launch year in the US and Germany, we are seeing this potential being realized, which is very gratifying."

The Cleveland Clinic has been compiling a list of what it considers the Top 10 Medical Innovations for the upcoming 12 months since 2007. The candidate technologies are identified by Cleveland Clinic staff from every major field in response to the question, "What innovations are 'game changers' in your field and will have the biggest impact on health care in 2013?" This year, the process yielded 150 emerging technologies, 55 of which were presented to two independent panels of leading Cleveland Clinic physicians. Each panel discussed, debated, and voted; then the two panels voted on the combined list and established the Top 10 Medical Innovations for 2013. 

For more information about MelaFind on the Top 10 Medical Innovations list for 2013, visit http://www.clevelandclinic.org/innovations/summit/topten/2013/five.html

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind®, and its further design and development.  MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

For Investors
Lynn Pieper
Westwicke Partners
415-202-5678

For Media
Claudia Beqaj